New company to be publicly listed as Citius Oncology, Inc.
Citius Pharmaceuticals, a biopharma company focused on the development and commercialization of critical care products, and TenX Keane Acquisition, a publicly traded special purpose acquisition company, announced a definitive agreement with a proposal to merge TenX and Citius Pharma's wholly owned oncology subsidiary that will continue as a public company listed on the Nasdaq exchange. With the new name of Citius Oncology, Inc., Citius Pharma will receive 67.5 million shares at $10 each and retain majority ownership of approximately 90%.
"We believe this transaction will allow us to unlock the value of Lymphir, and solidly position Citius Pharma to advance our diversified pipeline. This transaction will enable Citius Oncology, with access to the broader capital markets, to better support the successful commercialization of Lymphir, if approved, and explore additional potential targeted oncology therapies. Our majority ownership position and shared services agreement ensures that the Citius Pharma management team will remain fully engaged with the development and commercialization efforts at Citius Oncology. As previously announced, the company is in the process of formulating a plan of distribution of a portion of the shares of Citius Oncology to its shareholders. At Citius Pharma, we intend to focus on completing the Mino-Lok trial and continuing to evaluate next steps with our Halo-Lido program," stated Leonard Mazur, Chairman, CEO, Citius Pharma, in a company press release.
Reference: Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc. PR Newswire. October 24, 2023. Accessed October 24, 2023. https://www.prnewswire.com/news-releases/citius-pharmaceuticals-executes-definitive-agreement-to-merge-wholly-owned-subsidiary-with-tenx-keane-acquisition-to-form-publicly-listed-citius-oncology-inc-301965379.html
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.
Beyond the Scrubs: Understanding Healthcare Providers as People for Increased Engagement
March 28th 2024The benefits of adopting a humanized approach to healthcare provider marketing extend across the healthcare spectrum, enhancing engagement rates, brand loyalty, and marketing ROI, while also driving better outcomes for patients.